Skip to main content
SpringerLink
Log in

Endocrine resistance and breast cancer invasion

  • Chapter
Metastasis of Breast Cancer

Part of the book series: Cancer Metastasis – Biology and Treatment ((CMBT,volume 11))

Abstract

Despite the initial success of endocrine therapies, a significant proportion of women will acquire resistance to such treatments. Furthermore, clinical relapse during anti-hormonal therapy has been linked to tumours that have gained an aggressive phenotype and enhanced metastatic capacity and is frequently associated with a poorer outlook for the patient. Recently, we have demonstrated that the acquisition of an endocrine resistant state in breast cancer cells is accompanied by a profound increase in invasive capacity. Tumour cell invasion is fundamental to the subsequent development of metastasis, the most significant factor that affects the survival of patients with cancer. Despite this, past therapeutic approaches have paid relatively little attention to these important issues; thus a greater understanding of this process will lead to the identification of potential targets for anti-invasive intervention for such patients. To this end, we are currently addressing potential mechanisms which may underlie such processes in acquired anti-hormone resistance and have identified several molecular elements through the study of cell models of acquired endocrine resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nicholson RI, Johnston SR. Endocrine therapy-current benefits and limitations. Breast Cancer Res Treat 2005; 93:3-10.

    Article  CAS  Google Scholar 

  2. Nicholson RI, Robertson JFR, Hayes DF. Endocrine management of Breast Cancer, Taylor & Francis, London., RI Nicholson, JFR Robertson, and DF Hayes. eds., 2002; pp. 1-296.

    Google Scholar 

  3. Hiscox S, Morgan L, Barrow D, Dutkowski C, Wakeling A, Nicholson RI. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib (‘Iressa’, ZD1839). Clin. Exp Met 2004; 21:201-212.

    Article  CAS  Google Scholar 

  4. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI. Tamoxifen-resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation. Int J Cancer 2006; 118:290-301.

    Article  PubMed  CAS  Google Scholar 

  5. Hiscox S, Morgan L, Green T, Barrow D, Gee JM, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat 2006; 97:263-274.

    Article  PubMed  CAS  Google Scholar 

  6. Nicholson RI, Gee JM. Oestrogen and growth factor cross-talk and endocrine insen- sitivity and acquired resistance in breast cancer. Br J Cancer 2000; 82:501-513.

    Article  PubMed  CAS  Google Scholar 

  7. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37:9-15.

    Article  Google Scholar 

  8. Gee J, Rubini M, Robertson JF, Ellis IO, Gutteridge E, Nicholson RI. Type 1 insulin-like growth factor receptor expression and activation in clinical breast cancer. Breast Cancer Res Treat 2003; 82:S102.

    Google Scholar 

  9. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005; 12:99-111.

    Article  CAS  Google Scholar 

  10. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Non-endocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004; 10:346-354.

    Article  Google Scholar 

  11. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001; 8:175-182.

    Article  PubMed  CAS  Google Scholar 

  12. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann NY Acad Sci 2002; 963:104-115.

    Article  PubMed  CAS  Google Scholar 

  13. Yarden RI, Wilson MA, Chrysogelos SA. Estrogen suppression of EGFR expression in breast cancer cells: A possible mechanism to modulate growth. J Cell Biochem 2001; 81:232-246.

    Article  Google Scholar 

  14. Wilson MA, Chrysogelos SA. Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells. J Cell Biochem 2002; 85:601-614.

    Article  PubMed  CAS  Google Scholar 

  15. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JMW, Nicholson RI. Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth, Breast Cancer Res Treat 2005; in press.

    Google Scholar 

  16. Hutcheson IR, Knowlden JM, Barrow D, Jones HE, Nicholson RI. The novel ER down-regulator, Faslodex, modulates EGFR/MAPK activity in tamoxifenresistant MCF-7 breast cancer cells. Clin Cancer Res 2001; 7:A622.

    Google Scholar 

  17. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI. Oestrogen receptor-mediated modulation of the EGFR/MAPK path- way in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 2003; 81:81-93.

    Article  PubMed  CAS  Google Scholar 

  18. Gee J, Madden TA, Robertson JFR, Nicholson RI. Clinical response and resistance to SERMS, in: Endocrine Therapy in Breast Cancer, Robertson JFR, Nicholson RI, Hayes DF, eds., Martin Dunitz Ltd, London, 2002; pp. 155-190.

    Google Scholar 

  19. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 144:1032-1044.

    Article  PubMed  CAS  Google Scholar 

  20. Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijksen G. Over- expression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998; 425:145-150.

    Article  PubMed  CAS  Google Scholar 

  21. Kaufmann AM, Lichtner RB, Schirrmacher V, Khazaie K. Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis. Oncogene 1996; 13:2349-2358.

    PubMed  CAS  Google Scholar 

  22. Hsieh ET, Shepherd FA, Tsao MS. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. Lung Cancer 2002; 29:151-157.

    Article  Google Scholar 

  23. Seth D, Shaw K, Jazayeri J, Leedman PJ. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Br J Cancer 1999; 80:657-669.

    Article  PubMed  CAS  Google Scholar 

  24. Cai YC, Jiang Z, Vittimberga F, Xu X, Savas L, Woda B, Callery M, Banner B. Expression of transforming growth factor-alpha and epidermal growth factor receptor in gastrointestinal stromal tumours. Virchows Arch 1999; 435:112-115.

    Article  PubMed  CAS  Google Scholar 

  25. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer 2000; 89:484-487.

    Article  PubMed  CAS  Google Scholar 

  26. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284:31-53.

    Article  PubMed  CAS  Google Scholar 

  27. Schafer B, Gschwind A, Ullrich A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 2004; 23:991-999.

    Article  PubMed  CAS  Google Scholar 

  28. El-Obeid A, Bongcam-Rudloff E, Sorby M, Ostman A, Nister M, Westermark B. Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cells in vitro. Cancer Res 1997; 57:5598-5604.

    PubMed  CAS  Google Scholar 

  29. McCawley LJ, O’Brien P, Hudson LG. Overexpression of the epidermal growth factor receptor contributes to enhanced ligand-mediated motility in keratinocyte cell lines. Endocrinology 1997; 138:121-127.

    Article  PubMed  CAS  Google Scholar 

  30. Wakeling AE, Guy SP, Woodburn JR Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-5754.

    PubMed  CAS  Google Scholar 

  31. Fang KS, Ionides E, Oster G, Nuccitelli R, Isseroff RR. Epidermal growth factor receptor relocalization and kinase activity are necessary for directional migration of keratinocytes in DC electric fields. J Cell Sci 1999; 112:1967-1978.

    PubMed  CAS  Google Scholar 

  32. Ware JL. Growth factor network disruption in prostate cancer progression. Cancer Metastasis Rev 1998; 17:443-447.

    Article  PubMed  CAS  Google Scholar 

  33. Maheshwari G, Wiley HS, Lauffenburger DA. Autocrine epidermal growth factor signaling stimulates directionally persistent mammary epithelial cell migration. J Cell Biol 2001; 155:1123-1128.

    Article  PubMed  CAS  Google Scholar 

  34. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003; 2:345-351.

    PubMed  CAS  Google Scholar 

  35. Witters L, Engle L, Lipton A. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol Rep 2002; 9:1163-1166.

    PubMed  CAS  Google Scholar 

  36. Jones HE, Goddard L, Gee JMW, Hiscox S, Rubini M, Barrow D, Williams S, Wakeling AE, Nicholson RI. Insulin-like growth factor -1 receptor signalling and resistance to gefitinib (ZD1839; IRESSATM) in human breast and prostate cancer cells. Endocrine-Related Cancer 2004; 1:793-814.

    Article  CAS  Google Scholar 

  37. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Src-mediated phos- phorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is asso- ciated with modulation of receptor function. J Biol Chem 1999; 274:8335-8343.

    Article  PubMed  CAS  Google Scholar 

  38. Leu TH, Maa MC. Functional implication of the interaction between EGF receptor and c-Src. Front Biosci 2003; 8:S28-38.

    Article  PubMed  Google Scholar 

  39. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ. Mammary tumours expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 1994; 14:735-743.

    PubMed  CAS  Google Scholar 

  40. Tice DA, Biscardi JS, Nickles AL, Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 1999; 96:1415-1420.

    Article  PubMed  CAS  Google Scholar 

  41. Maa MC, Leu TH, McCarley DJ, Schatzman RC, Parsons SJ. Potentiation of epi- dermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc Natl Acad Sci USA 1995; 92: 6981-6985.

    Article  PubMed  CAS  Google Scholar 

  42. Biscardi JS, Belsches AP, Parsons SJ. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumour cells. Mol Carcinog 1998; 21:261-272.

    Article  PubMed  CAS  Google Scholar 

  43. Schwartzberg PL, Xing L, Hoffmann O, Lowell CA, Garrett L, Boyce BF, Varmus HE. Rescue of osteoclast function by transgenic expression of kinasedeficient Src in src-/- mutant mice.Genes Dev 1997; 11:2835-2844.

    Article  PubMed  CAS  Google Scholar 

  44. Kaplan KB, Swedlow JR, Morgan DO, Varmus HE. c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev 1995; 9:1505-1517.

    Article  PubMed  CAS  Google Scholar 

  45. Fincham VJ, Frame MC. The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility. Embo J 1998; 17:81-92.

    Article  PubMed  CAS  Google Scholar 

  46. Jones RJ, Avizienyte E, Wyke AW, Owens DW, Brunton VG, Frame MC. Elevated c-Src is linked to altered cell-matrix adhesionn rather than proliferation in KM12C human colorectal cancer cells. Br J Cancer 2002; 87:1128-1135.

    Article  PubMed  CAS  Google Scholar 

  47. Irby RB, Yeatman TJ. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res 2004; 62:2669-2674.

    Google Scholar 

  48. Boyer B, Roche S, Denoyelle M, Thiery JP. Src and Ras are involved in separate pathways in epithelial cell scattering. Embo J 1997; 16:5904-5913.

    Article  PubMed  CAS  Google Scholar 

  49. Boyer B, Bourgeois Y, Poupon MF.Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 2002; 21:2347-2356.

    Article  PubMed  CAS  Google Scholar 

  50. Masaki T, Okada M, Shiratori Y, Rengifo W, Matsumoto K, Maeda S, Kato N, Kanai F, Komatsu Y, Nishioka M, Omata M. pp60c-src activation in hepato- cellular carcinoma of humans and LEC rats. Hepatology 1998; 27:1257-1264.

    Article  PubMed  CAS  Google Scholar 

  51. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, Li JQ, Yoneyama H, Uchida N, Fujita J, Yoshiji H, Watanabe S, Kurokohchi K, Kuriyama S. pp60c-src activation in lung adenocarcinoma. Eur J Cancer 2003; 39:1447-1455.

    Article  PubMed  CAS  Google Scholar 

  52. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE. Activated SRC protein tyrosine kinase is over- expressed in late-stage human ovarian cancers. Gynecol Oncol 2003; 88:73-79.

    Article  PubMed  CAS  Google Scholar 

  53. Summy JM, Gallick GE. Src family kinases in tumour progression and metastasis. Cancer Metastasis Rev 2003; 22:337-358.

    Article  PubMed  CAS  Google Scholar 

  54. Hennequin LF, Allen J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Olivier R, Plé PA, Warin N, Costello G. The discovery of N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530) a novel highly selective, orally available, dual-specific Src/abl kinase inhibitor. J Med Chem 2006; in press.

    Google Scholar 

  55. Morgan LD, Hiscox S, Nicholson RI. Elevated Src kinase activity accompanies endocrine resistance in breast cancer and promotes an aggressive cell phenotype. Proc Adv Breast Cancer Res: Gen Biol Clin Appl 2005; B54.

    Google Scholar 

  56. Hiscox SE, Barrow D, Green T, Nicholson RI. Adhesion independent focal adhesion kinase activation involves Src and promotes cell adhesion and motility in tamoxifen-resistant MCF-7 cells and is inhibited by the Src/Abl kinase inhibitor, AZD0530. Proc Am Ass Cancer Res 2005; 46:A266.

    Google Scholar 

  57. Hiscox S, Morgan L, Green TP, Nicholson RI. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Rel Cancer 2006; in press.

    Google Scholar 

  58. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden J, Gee JM, Nicholson RI. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001; 142:2776-2788.

    Article  PubMed  CAS  Google Scholar 

  59. Giles MG, Fiegl H, Widschwendter M, Gee JM, Wakeling AE, Nicholson RI. Irreversible loss of oestrogen receptor expression in MCF-7 cells following long-term exposure to fulvestrant. Breast Cancer Res Treat 2006; in press.

    Google Scholar 

  60. Cheung KL, Nicholson RI, Blamey RW, Robertson JF. Selection of primary breast cancer patients for adjuvant endocrine therapy-is oestrogen receptor alone adequate? Breast Cancer Res Treat 2001; 65:155-162.

    Article  PubMed  CAS  Google Scholar 

  61. Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO. Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv Anat Pathol 2005; 12:271-273.

    Article  PubMed  CAS  Google Scholar 

  62. Khirwadkar Y, Jordan NJ, Hiscox SE, Nicholson RI. Increased matrix metallo- proteinase (MMP) expression in anti-oestrogen resistant breast carcinoma cell lines. Eur J Cancer 2005; 3:P19.

    Google Scholar 

  63. Burmi RS, McClelland RA, Nicholson RI, Barrow D, Ellis IO, Robertson JF, Gee JM. Microarray studies reveal novel genes associated with antiestrogen resistance in breast cancer. Proc Adv Breast Cancer Res: Genetics, Biology and Clin Appl 2005; A22.

    Google Scholar 

  64. Gee J, Shaw V, Burmi R, McClelland R, Morgan H, Harper M, Hiscox S, Barrow D, Lewis P, Nicholson RI. Array profiling of survival and resistance genes in anti-hormone-treated breast cancer cells. Intl J Mol Med 2004; 14:S81.

    Google Scholar 

  65. Harper ME, Smith C, Nicholson RI. Upregulation of CD44s and variants in anti-hormone resistant breast cancer cells. Eur J Cancer 2005; 3:A25.

    Google Scholar 

  66. Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C, Nicholson RI. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocr Rel Cancer 2006; in press.

    Google Scholar 

  67. Jiang WG, Hiscox S. Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histol Histopathol 1997; 12:537-555.

    PubMed  CAS  Google Scholar 

  68. Parr C, Jiang WG. Hepatocyte growth factor activators, inhibitors and antagonists and their implication in cancer intervention. Histol Histopathol 2001; 16:251-268.

    PubMed  CAS  Google Scholar 

  69. Edakuni G, Sasatomi E, Satoh T, Tokunaga O, Miyazaki K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 2001; 51:172-178.

    Article  PubMed  CAS  Google Scholar 

  70. Parr C, Jiang W G. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int J Oncol 2001; 19:857-863.

    PubMed  CAS  Google Scholar 

  71. Camp RL, Rimm EB, Rimm DL. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86:2259-2265.

    Google Scholar 

  72. Elliott BE, Hung WL, Boag AH, Tuck AB. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol 2002; 80:91-102.

    Article  PubMed  CAS  Google Scholar 

  73. Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, Rimm DL. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998; 82:1513-1520.

    Article  PubMed  CAS  Google Scholar 

  74. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic signi- ficance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 2005; 11:2222-2228.

    Article  PubMed  CAS  Google Scholar 

  75. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Hardeck D. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005; 113:678-682.

    Article  PubMed  CAS  Google Scholar 

  76. Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG, Camp RL, Rimm DL. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003; 97:1841-1848.

    Article  PubMed  CAS  Google Scholar 

  77. Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003; 94:321-327.

    Article  PubMed  CAS  Google Scholar 

  78. Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, Laccabue D, Supino R, Belluco S, Favini E, Poletti A, Zunino F. Inhibition of c- Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther 2006; 5:2388-2397.

    Article  PubMed  CAS  Google Scholar 

  79. Wang SY, Chen B, Zhan YQ, Xu WX, Li CY, Yang RF, Zheng H, Yue PB, Larsen SH, Sun HB, Yang X. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 2004; 41:267-273.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, CF10 3XF, Heath Park, Cardiff, UK

    Stephen Hiscox

  2. Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, CF10 3XF, Heath Park, Cardiff, UK

    Julia Gee

  3. Cancer Pharmacology School of Pharmacy, Cardiff University, Redwood Building, Cardiff, UK

    Robert I. Nicholson PhD

Authors
  1. Stephen Hiscox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Gee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert I. Nicholson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, Cardiff University School of Medicine, Heath Park, CF14 4XN, Cardiff, UK

    Robert E. Mansel MS, FRCS, CBE

  2. Michell Cancer Institute, University of South Alabama, 307 N. University Blvd., 2015, 36688, AL, USA

    Oystein Fodstad PhD

  3. Metastasis and Angiogenesis Research Group, Cardiff University School of Medicine, CF14 4XN, Heath Park, Cardiff, UK

    Wen G. Jiang MB, BCh, MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer

About this chapter

Cite this chapter

Hiscox, S., Gee, J., Nicholson, R.I. (2007). Endocrine resistance and breast cancer invasion. In: Mansel, R.E., Fodstad, O., Jiang, W.G. (eds) Metastasis of Breast Cancer. Cancer Metastasis – Biology and Treatment, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5867-7_7

Download citation

Publish with us

Policies and ethics

Search

Navigation